Metabolic programs drive function of therapeutic NK cells in hypoxic tumor environments

Philippa R. Kennedy,Upasana Sunil Arvindam,Shee Kwan Phung,Brianna Ettestad,Xueyang Feng,Yunmin Li,Quinlan M. Kile,Peter Hinderlie,Melissa Khaw,Rih-Sheng Huang,Marissa Kaufman,Patrycja Puchalska,Amanda Russell,Jonah Butler,Lucas Abbott,Paul McClure,Xianghua Luo,Quynhanh T. Lu,Bruce R. Blazar,Peter A. Crawford,James Lim,Jeffrey S. Miller,Martin Felices
DOI: https://doi.org/10.1126/sciadv.adn1849
IF: 13.6
2024-11-01
Science Advances
Abstract:Limited oxygen (hypoxia) in solid tumors poses a challenge to successful immunotherapy with natural killer (NK) cells. NK cells have impaired cytotoxicity when cultured in hypoxia (1% oxygen) but not physiologic (>5%) or atmospheric oxygen (20%). We found that changes to cytotoxicity were regulated at the transcriptional level and accompanied by metabolic dysregulation. Dosing with interleukin-15 (IL-15) enhanced NK cell cytotoxicity in hypoxia, but preactivation with feeder cells bearing IL-21 and 4-1BBL was even better. Preactivation resulted in less perturbed metabolism in hypoxia; greater resistance to oxidative stress; and no hypoxia-induced loss of transcription factors (T-bet and Eomes), activating receptors, adhesion molecules (CD2), and cytotoxic proteins (TRAIL and FasL). There remained a deficit in CD122/IL-2Rβ when exposed to hypoxia, which affected IL-15 signaling. However, tri-specific killer engager molecules that deliver IL-15 in the context of anti-CD16/FcγRIII were able to bypass this deficit, enhancing cytotoxicity of both fresh and preactivated NK cells in hypoxia.
multidisciplinary sciences
What problem does this paper attempt to address?